The study found that patients exhibited a low rate of severe side effects after returning home, supporting less-intensive ...
Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy ...
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the ...
Zev A. Wainberg, MD, MSc, discussed why neither the first-line regimen nor the second-line chemotherapy comparator altered ...
The investigators report that the phase 1 portion of the COMPARE trial met its safety end point and cleared the study to ...
If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the ...
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in ...
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast ...
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma. “If it is successful, you should be able to access this combination ...
ESMO 2026 posters showed durable EV-302 benefit in older and comorbid populations plus persistent early mortality in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results